ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL2108041
CHEMBL2108041
Compound Name OCRELIZUMAB
ChEMBL Synonyms PR-070769 | OCRELIZUMAB | 2H7 | R-1594 | OCREVUS | RG-1594
Max Phase 4 (Approved)
Trade Names OCREVUS

Sources

  • Clinical Candidates
  • Manually Added Drugs
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Molecule Features

CHEMBL2108041 compound icon
Drug Type:Antibody Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:N Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
B-lymphocyte antigen CD20 other B-lymphocyte antigen CD20 PubMed

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Immune System DiseasesD007154EFO:0000540immune system disease4ATC
Lymphoma, Non-HodgkinD008228EFO:0005952non-Hodgkins lymphoma1ClinicalTrials
Multiple Sclerosis, Relapsing-RemittingD020529EFO:0003929relapsing-remitting multiple sclerosis4ClinicalTrials
FDA
Lupus Erythematosus, SystemicD008180EFO:0002690systemic lupus erythematosus3ClinicalTrials
Arthritis, RheumatoidD001172EFO:0000685rheumatoid arthritis3ClinicalTrials
Multiple SclerosisD009103EFO:0003885multiple sclerosis3ClinicalTrials
Multiple Sclerosis, Chronic ProgressiveD020528EFO:0003840chronic progressive multiple sclerosis4ClinicalTrials
FDA

Clinical Data

ClinicalTrials.gov OCRELIZUMAB
The Cochrane Collaboration OCRELIZUMAB

Compound Cross References

ATC L - ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 - IMMUNOSUPPRESSANTS
L04A - IMMUNOSUPPRESSANTS
L04AA - Selective immunosuppressants
L04AA36 - ocrelizumab

ChemSpider ChemSpider Identifier not yet assigned
DailyMed ocrelizumab
spacer
spacer